Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith Regan

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of the National Cancer Institute|September 27, 2015
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP), Christopher Sweeney, Mari Nakabayashi, et al.
The Prostate|August 1, 2008
Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapyKerstyn M Haram, Heidi J Peltier, Bin Lu, et al.
Radiology|May 29, 2009
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?Rachel Schor-Bardach, David C Alsop, Ivan Pedrosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerMing Yang, Wanling Xie, Elahe Mostaghel, et al.
Breast Cancer Research : BCR|September 30, 2025
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II studyKristina Fanucci, Eren D Yeh, Ruichao Shi, et al.
Breast Cancer Research and Treatment|December 28, 2023
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancerFaina Nakhlis, Samuel M Niman, Naoto T Ueno, et al.
Journal of the National Cancer Institute|October 1, 2011
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupMitch Dowsett, Torsten O Nielsen, Roger A'Hern, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of the National Cancer Institute|September 27, 2015
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP), Christopher Sweeney, Mari Nakabayashi, et al.
The Prostate|August 1, 2008
Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapyKerstyn M Haram, Heidi J Peltier, Bin Lu, et al.
Radiology|May 29, 2009
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?Rachel Schor-Bardach, David C Alsop, Ivan Pedrosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerMing Yang, Wanling Xie, Elahe Mostaghel, et al.
Breast Cancer Research : BCR|September 30, 2025
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II studyKristina Fanucci, Eren D Yeh, Ruichao Shi, et al.
Breast Cancer Research and Treatment|December 28, 2023
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancerFaina Nakhlis, Samuel M Niman, Naoto T Ueno, et al.
Journal of the National Cancer Institute|October 1, 2011
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupMitch Dowsett, Torsten O Nielsen, Roger A'Hern, et al.
Pageof 3